Long-acting injectable antipsychotics in the treatment of schizophrenia: Their role in relapse prevention

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 14, 2010, Pages 2301-2317

  Agid, Ofer ^a,b   Foussias, George ^a,b   Remington, Gary ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antipsychotics; Long acting injectable antipsychotics; Schizophrenia; Second generation antipsychotics

Indexed keywords

LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; RISPERIDONE;

CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; HOSPITAL READMISSION; HUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RELAPSE; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS; MEDICATION ADHERENCE; RECURRENCE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 77956575798     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.499125     Document Type: Review

References (206)

1. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247 (Pubitemid 29125132)
2. Kane JM. Schizophrenia. N Engl J Med 1996;334:34-41
3. Hogarty GE, Goldberg SC, Schooler NR. Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients. Arch Gen Psychiatry 1974;31:609-618
4. Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Arch Gen Psychiatry 1974;31:603-608
5. Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. Br Med J 1971;3:599-604
6. Rifkin A, Quitkin F, Klein DF. Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data. Arch Gen Psychiatry 1977;34:1215-1219 (Pubitemid 8216734)
7. Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry 1975;132:1237-1245
8. Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47:741-773
9. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002;106:286-290
10. Kissling W. Guidelines for neuroleptic relapse prevention in schizophrenia. In: Kissling W, editor, Guidelines for neuroleptic relapse prevention in schizophrenia. Springer Verlag, Berlin; 1991. p. 1-6
11. Kissling W. Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand Suppl 1994;382:16-24
12. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
13. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201
14. Carrick, JA. Medical ethics in the ancient world. Georgetown University Press, Washington DC; 2001
15. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497
16. Dimatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200-209
17. Berg JS, Dischler J, Wagner DJ, et al. Medication compliance: a healthcare problem. Ann Pharmacother 1993;27:S1-24
18. Takemoto SK, Pinsky BW, Schnitzler MA, et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant 2007;7:2704-2711
19. Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008;3:371-384
20. Haynes RB, Taylor DW, Sackett DL, editors. Compliance in health care. Johns Hopkins University Press, Baltimore; 1979
21. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64:1308-1315
22. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 2008;161:235-247
23. Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl 1994;382:11-15
24. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002;159:1653-1664
25. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 2006;67:1542-1550
26. Weiden P, Rapkin B, Zygmunt A, et al. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 1995;46:1049-1054
27. Patel MX, David AS. Why aren't depot antipsychotics prescribed more often, and what can be done about it? Adv Psychiatr Treat 2005;11:203-213
28. Budd RJ, Hughes IC, Smith JA. Health beliefs and compliance with antipsychotic medication. Br J Clin Psychol 1996;35:393-397
29. Smith J, Hughes ICT, Budd RJ. Non-compliance with antipsychotic medication. User's view on advantages and disadvantages. J Ment Health 1999;8:287-296
30. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
31. Tegeler J, Lehmann E. A follow-up study of schizophrenic outpatients treated with depot-neuroleptics. Prog Neuropsychopharmacol 1981;5:79-90
32. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128
33. Bergiannaki JD, Hatzimanolis J, Liappas J, et al. Relapse prevention in schizophrenia: attitudes of neurologists-psychiatrists. Eur Psychiatry 2001;16:90-98
34. Hughes IH, Budd R. Compliance with antipsychotic medication: from theory to practice. J Ment Health 1997;6:473-489
35. Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994;20:297-310
36. Naber D, Karow A. Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol 2001;11(Suppl 4):S391-6
37. Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res 2010;175:58-62
38. Diaz E, Levine HB, Sullivan MC, et al. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci 2001;26:325-329
39. Babiker IE. Noncompliance in schizophrenia. Psychiatr Dev 1986;4:329-337
40. Remington G, Kwon J, Collins A, et al. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res 2007;90:229-237
41. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-3277
42. Shriqui CL. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen. Can J Psychiatry 1995;40:S38-48
43. Tauscher J, Kapur S. Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs 2001;15:671-678
44. Kikkert MJ, Barbui C, Koeter MW, et al. Assessment of medication adherence in patients with schizophrenia: the Achilles heel of adherence research. J Nerv Ment Dis 2008;196:274-281
45. Kane JM. Treatment adherence and long-term outcomes. CNS Spectr 2007;12:21-26
46. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):3-8
47. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999;60(Suppl 21):25-30
48. Valenstein M, Copeland LA, Owen R, et al. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001;62:545-551
49. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-891
50. Docherty J, Mahmoud R, Grogg A, Kozma C. Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. In: 9th International Congress on Schizophrenia Research; 29 March - 02 April 2003, Colarado Springs, Colorado; 2003; 60(1):281-282
51. Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008;69:47-53
52. Carpenter WT Jr, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147:1138-1148
53. Gaebel W, Frick U, Kopcke W, et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? Br J Psychiatry Suppl 1993;21:8-12
54. Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry 1991;48:333-339
55. Jolley AG, Hirsch SR, Morrison E, et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990;301:837-842
56. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry 1997;54:453-463
57. Goldberg SC, Schooler NR, Hogarty GE, Roper M. Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Arch Gen Psychiatry 1977;34:171-184
58. Carpenter W Jr. Early, targeted pharmacotherapeutic intervention in schizophrenia. J Clin Psychiatry 1986;47(Suppl):23-29
59. Carpenter WT Jr. Maintenance therapy of persons with schizophrenia. J Clin Psychiatry 1996;57(Suppl 9):10-18
60. Remington G, Seeman P, Shammi C, et al. 'Extended' antipsychotic dosing: rationale and pilot data. J Clin Psychopharmacol 2005;25:611-613
61. Remington G, Feingold A, et al. 'Extended' antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind trial. J Clin Psychiatry 2010; In press
62. Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000;18:106-124
63. Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the 'revolving door' phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995;152:856-861
64. Sullivan G, Wells KB, Morgenstern H, Leake B. Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry 1995;152:1749-1756
65. Ayuso-Gutierrez JL, Del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997;28:199-206
66. Kane JM, Rifkin A, Quitkin F, et al. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982;39:70-73
67. Rabiner CJ, Wegner JT, Kane JM. Outcome study of first-episode psychosis. I: Relapse rates after 1 year. Am J Psychiatry 1986;143:1155-1158
68. Gaebel W, Pietzcker A. One-year outcome of schizophrenic patients - the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry 1985;18:235-239
69. Johnstone EC, Crow TJ, Johnson AL, Macmillan JF. The Northwick Park Study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission. Br J Psychiatry 1986;148:115-120
70. The Scottish first episode schizophrenia study. VIII. Five-year follow-up: clinical and psychosocial findings. The Scottish Schizophrenia Research Group. Br J Psychiatry 1992;161:496-500
71. Crow TJ, Macmillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986;148:120-127
72. Geddes J, Mercer G, Frith CD, et al. Prediction of outcome following a first episode of schizophrenia. A follow-up study of Northwick Park first episode study subjects. Br J Psychiatry 1994;165:664-668
73. Rajkumar S, Thara R. Factors affecting relapse in schizophrenia. Schizophr Res 1989;2:403-409
74. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003;64(Suppl 16):34-40
75. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-429
76. Birnbaum M, Sharif Z. Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER. Patient Prefer Adherence 2008;2:233-240
77. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564
78. Lapierre YD, Angus C, Awad AG, et al. The treatment of negative symptoms: a clinical and methodological study. Int Clin Psychopharmacol 1999;14:101-112
79. Simpson GM. A brief history of depot neuroleptics. J Clin Psychiatry 1984;45:3-4
80. Kinross-Wright J, Vogt AH, Charalampous KD. A new method of drug therapy. Am J Psychiatry 1963;119:779-780
81. Chue P, Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 2007;21:441-448
82. Johnson DA, Freeman H. Long-acting tranquillizers. Practitioner 1972;208:395-400
83. Curry SH, Whelpton R, De Schepper PJ, et al. Plasma-fluphenazine concentrations after injection of long-acting esters. Lancet 1978;1:1217-1218
84. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry 2009;195:S13-19
85. Citrome L. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 2009;64(2):216-239
86. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992;53:426-433
87. Agid O, Kapur S, Remington G. Emerging drugs for schizophrenia. Expert Opin Emerg Drugs 2008;13:479-495
88. Kane JM, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64(Suppl 12):5-19
89. Alessi-Severini S, Biscontri RG, Collins DM, et al. Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996 - 2006. Psychiatr Serv 2008;59:547-553
90. Aparasu RR, Bhatara V, Gupta S. U S. national trends in the use of antipsychotics during office visits, 1998 - 2002. Ann Clin Psychiatry 2005;17:147-152
91. IMS health Inc. Marketing Research. In: Geddes J. Generating evidence to inform policy and practice: the example of the second generation "Atypical" antipsychotics. Schizophrenia Bulletin 2003;29(1):105-114
92. Keith S. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Expert Rev Neurother 2009;9:9-31
93. Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R D 2005;6:129-137
94. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-1257
95. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132
96. Lasser RA, Bossie CA, Gharabawi GM, Baldessarini RJ. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol 2005;8:427-438
97. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004;65:1084-1089
98. Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry 2009;195(Suppl 52):S29-36
99. Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69:790-799
100. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167:181-189
101. Owen RT. Olanzapine: a review of rapid and long-acting parenteral formulations. Drugs Today (Barc) 2010;46:173-181
102. Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010. [Epub ahead of print]
103. Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010;30:235-244
104. Nahata T, Saini TR. Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design. PDA J Pharm Sci Technol 2009;63:113-122
105. Jann MW, Ereshefsky L, Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 1985;10:315-333
106. Dencker SJ. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. J Clin Psychiatry 1984;45:22-27
107. Marder SR, Hubbard JW, Van Putten T, Midha KK. Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications. Psychopharmacology (Berl) 1989;98:433-439
108. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006;67(Suppl 5):15-18
109. Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995;9(Suppl 5):17-20
110. Young JL, Spitz RT, Hillbrand M, Daneri G. Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments, and prospects. J Am Acad Psychiatry Law 1999;27:426-444
111. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986;14:105-122
112. Shi L, Ascher-Svanum H, Zhu B, et al. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 2007;58:482-488
113. Tattan TM, Creed FH. Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull 2001;27:149-155
114. Dencker S. Neuroleptic relapse prevention. In Kissling W, editor, Guidelines for neuroleptic relapse prevention in Schizophrenia. Springer, Berlin; 1991. p. 24-25
115. Lee SH, Choi TK, Suh S, et al. Effectiveness of a psychosocial intervention for relapse prevention in patients with schizophrenia receiving risperidone via long-acting injection. Psychiatry Res 2010;175:195-199
116. Kane JM. The use of depot neuroleptics: clinical experience in the United States. J Clin Psychiatry 1984;45:5-12
117. Blackburn HL, Allen JL. Behavioral effects of interrupting and resuming tranquilizing medication among schizophrenics. J Nerv Ment Dis 1961;133:303-308
118. Diamond LS, Marks JB. Discontinuance of tranquilizers among chronic schizophrenic patients receiving maintenance dosage. J Nerv Ment Dis 1960;131:247-251
119. Engelhardt DM, Rosen B, Freedman N, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization - a reevaluation. Arch Gen Psychiatry 1967;16:98-101
120. Itil T, Keskiner A. Fluphenazine hydrochloride, enanthate, and decanoate in the management of chronic psychosis. Dis Nerv Syst 1970;31(Suppl):37-42
121. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-299
122. Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006;333:224-227
123. Zhu B, Ascher-Svanum H, Shi L, et al. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv 2008;59:315-317
124. Conley RR, Kelly DL, Love RC, McMahon RP. Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry 2003;15:23-31
125. Haro JM, Novick D, Suarez D, et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006;26:571-578 (Pubitemid 44772733)
126. Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007;17:235-244
127. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry 2009;195:S20-S28
128. Denham J, Adamson L. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatr Scand 1971;47:420-430
129. Denham J, Adamson L. Long-acting phenothiazines in the prevention of relapse of schizophrenic patients. Can Psychiatr Assoc J 1973;18:235-237
130. Devito RA, Brink L, Sloan C, Jolliff F. Fluphenazine decanoate vs oral antipsychotics: a comparison of their effectiveness in the treatment of schizophrenia as measured by a reduction in hospital readmissions. J Clin Psychiatry 1978;39:26-34
131. Freeman H. Twelve years' experience with the total use of depot neuroleptics in a defined population. Adv Biochem Psychopharmacol 1980;24:559-564
132. Gottfries CG, Green L. Flupenthixol decanoate - in treatment of out-patients. Acta Psychiatr Scand Suppl 1974;255:15-24
133. Marriott P, Hiep A. A mirror image out-patient study at a depot phenothiazine clinic. Aust NZ J Psychiatry 1976;10:163-167
134. Davis JM, Dysken MW, Haberman SJ, et al. Use of survival curves in analysis of antipsychotic relapse studies. Adv Biochem Psychopharmacol 1980;24:471-481
135. Johnson DA, Pasterski G, Ludlow JM, et al. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 1983;67:339-352
136. Youssef H. A five year follow-up study of chronic schizophrenics and other psychotics treated in the community: depot haloperidol decanuate versus other neuroleptics. Adv Ther 1989;64:186-195
137. Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 2006;114:14-20
138. Barnes TR, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994;10:464-479
139. Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006;67:1948-1953
140. Levine J, Schooler NR, Cassano GB. The role of depot neuroleptics in the treatment of schizophrenic patients. Psychol Med 1979;9:383-386
141. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56
142. Dencker SJ, Axelsson R. Optimising the use of depot antipsychotics. CNS Drugs 1996;367-381
143. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998;8:55-66
144. Ereshefsky L, Saklad SR, Jann MW, et al. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984;45:50-59
145. Nagy A. Blood and brain concentrations of imipramine, clomipramine and their monomethylated metabolites after oral and intramuscular administration in rats. J Pharm Pharmacol 1977;29:104-107
146. Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004;70:91-100
147. Yoshimura R, Ueda N, Ikenouch-Sugita A, et al. Fluctuating plasma levels of the active moiety of risperidone is related to occurrence of extrapyramidal symptoms. Int J Psychiatry Clin Pract 2009;13:21-24
148. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520
149. Remington GJ, Adams ME. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995;40:S5-11
150. Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther 2004;26:1994-2002
151. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007;115:260-267
152. Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 2003;29:531-540
153. Taylor D. Atypical antipsychotics in the treatment of schizophrenia. Pragmatic considerations are important when considering which drug to prescribe. BMJ 2001;322:925
154. Hamann J, Langer B, Leucht S, et al. Medical decision making in antipsychotic drug choice for schizophrenia. Am J Psychiatry 2004;161:1301-1304
155. Galletly CA. Antipsychotic drug doses in a schizophrenia inpatient unit. Aust NZ J Psychiatry 1992;26:574-576
156. Johnson DA, Wright NF. Drug prescribing for schizophrenic out-patients on depot injections. Repeat surveys over 18 years. Br J Psychiatry 1990;156:827-834
157. Heres S, Hamann J, Mendel R, et al. Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1987-1993
158. Sim K, Su A, Ungvari GS, et al. Depot antipsychotic use in schizophrenia: an East Asian perspective. Hum Psychopharmacol 2004;19:103-109
159. Barnes TR, Paton C, Cavanagh MR, et al. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007;33:1397-1403
160. Barnes TR, Paton C, Hancock E, et al. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr Scand 2008;118:26-33
161. Paton C, Barnes TR, Cavanagh MR, et al. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 2008;192:435-439
162. Johnson D. UK: neuroleptic relapse prevention. In: Kissling W, editor, Guidelines for neuroleptic relapse prevention in schizophrenia. Springer, Berlin; 1991. p. 45-46
163. Fleischhacker WW. The current status of maitenance treatment in schizophrenia. In: Kissling W, editor, Guidelines for neuroleptic relapse prevention in schizophrenia. Springer, Berlin; 1991. p. 13-15
164. West JC, Wilk JE, Olfson M, et al. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv 2005;56:283-291
165. Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002;28:17-29
166. Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull 1998;24:11-20; discussion 20-32
167. Callaly T, Trauer T. Patterns of use of antipsychotic medication in a regional community mental health service. Australas Psychiatry 2000;8:220-224
168. Paton C, Lelliott P, Harrington M, et al. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol 2003;17:223-229
169. Kane J, Garcia-Ribera C. clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry 2009;195:S63-S67
170. Glazer WM. The depot paradox. Behav Healthc 2007;27:44-46
171. NICE (National Institute for Health and Clinical Excellence). Schizophrenia: Full National Clinical Guideline on Core Interventions in Primary and Secondary Care. London: Gaskell/British Psychological Society; 2003
172. Canadian Psychiatric Association. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry 2005;50:7-56S
173. Lieberman JA, Perkins D, Belger A, et al. The early stages ofschizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-897
174. Patel MX, De Zoysa N, Bernadt M, David A. Depot and oral antipsychotics: patient ps and attitudes are not the same thing. J Psychopharmacol 2009;23:789-796
175. Patel MX, De Zoysa N, Baker D, David AS. Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs 2005;12:237-244
176. Glover G, Malcolm G. The prevalence of depot neuroleptic treatment among West Indians and Asians in the London borough of Newham. Soc Psychiatry Psychiatr Epidemiol 1988;23:281-284
177. Price N, Glazer W, Morgenstern H. Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients. Am J Psychiatry 1985;142:1491-1492
178. Cournos F, Mckinnon K, Stanley B. Outcome of involuntary medication in a state hospital system. Am J Psychiatry 1991;148:489-494
179. Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-307
180. Waddell L, Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry 2009;195:S43-50
181. Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 2007;22:275-282
182. Glazer WM. Depot fluphenazine: risk/benefit ratio. J Clin Psychiatry 1984;45:28-35
183. Marder SR, Van Putten T, Mintz J, et al. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984;41:1025-1029
184. Patel M, De Zoysa N, Bernadt M, et al. Are depot antipsychotics more coercive than tablets? J Psychopharmacol 2009. [Epub ahead of print]
185. Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 1997;95:464-468
186. Svedberg B, Backenroth-Ohsako G, Lutzen K. On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medication. Int J Ment Health Nurs 2003;12:110-118
187. Wistedt B. How does the psychiatric patient feel about depot treatment, compulsion or help? Nord J Psychiatry 1995;49:41-46
188. Lieberman JA, Sheitman B, Chakos M, et al. The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. J Clin Psychopharmacol 1998;18:20S-24S
189. Olfson M, Mechanic D, Hansell S, et al. Prediction of homelessness within three months of discharge among inpatients with schizophrenia. Psychiatr Serv 1999;50:667-673
190. Sokal J, Messias E, Dickerson FB, et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis 2004;192:421-427
191. Edwards J, Maude D, Herrmann-Doig T, et al. A service response to prolonged recovery in early psychosis. Psychiatr Serv 2002;53:1067-1069
192. Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry 1999;60(Suppl 23):5-9
193. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):9-14
194. Kim B, Lee SH, Choi TK, et al. Effectiveness of risperidone long-acting
195. Emsley R, Oosthuizen P, Koen L, et al. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 2008;23:325-331
196. Weiden PJ, Schooler NR, Weedon JC, et al. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 2009;70:1397-1406
197. Davis JM, Chen N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry 2003;64(Suppl 16):24-33
198. Adil S, Virani Kzb-B, Jeffries JJ, editors. Clinical handbook of psychotropic drugs. 18th revised edition. Hogrefe & Huber, Ohio; 2009
199. Reynolds JEF. Martindale the extra pharmacopoeia: Anxiolytic Sedatives Hypnotics and Neuroleptics. 30th edition. Pharmaceutical Press, London; 1993
200. Dencker SJ, Malm U, Jorgensen A, Overo KF. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. IV. Serum levels and clinical outcome. Acta Psychiatr Scand 1980;279(Suppl):55-63 (Pubitemid 10145271)
201. Curry SH, Whelpton R, De Schepper PJ, et al. Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol 1979;7:325-331
202. Beresford R, Ward A. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 1987;33:31-49
203. Larsson M, Axelsson R, Forsman A. On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate. Curr Ther Res 1984;36:1071-1088
204. Aaes-Jorgensen T. Pharmacokinetics of three different injectable zuclopenthixol preparations. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:77-85
205. Gopal S, Gassmann-Mayer C, Palumbo J, et al. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin 2010;26:377-387
206. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with Schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet 2009;48:585-600